Found 131 clinical trials
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease
- 322 views
- 08 Dec, 2020
- 1 location
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures. This might allow more people to have a transplant. Objective: To see if a new transplant regime is effective, safe and well …
- 83 views
- 22 Dec, 2020
- 1 location
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
adolescent participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Day 28.
- 0 views
- 14 Dec, 2021
- 17 locations
Fecal Microbiota Transplantation in aGvHD After ASCT
Acute graft-versus-host-disease (aGvHD) is a typical complication after allogeneic hematopoetic stem cell transplantation (ASCT). About 30-60% of patients after ASCT are affected by aGvHD, which
- 0 views
- 23 Apr, 2022
- 1 location
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for grade 3-4
- 0 views
- 02 Sep, 2021
- 1 location
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)
-Refractory acute Graft-Versus-Host Disease (SR-aGVHD). The primary hypothesis is that T-Guard treatment will improve the Day 28 complete response (CR) rate in patients with Grades III and IV SR-aGVHD
- 0 views
- 10 May, 2022
- 5 locations
Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
The purpose of this study is to determine the response and toxicity rate of two different dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in
- 0 views
- 21 Dec, 2021
- 1 location
Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
The purpose of this study is to determine the response and toxicity rate of two different dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in
- 0 views
- 24 Mar, 2022
- 1 location
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT
bladder is also considered to be one of the immune attacked organs in acute graft-versus-host disease (aGVHD). The classic treatments for HC include hydration, alkalization, and bladder irrigation
- 1 views
- 18 Sep, 2021
- 1 location
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS
An "intention-to-treat" study to evaluate the impact of allogeneic HSCT with Total Marrow and Lymphoid irradiation (TMLI), followed by Treg/Tcon adoptive immunotherapy, on overall survival in patients affected by Myelodysplastic Syndrome (MDS), according to IPSS-R.
- 0 views
- 27 Mar, 2021
- 1 location